Cargando…
Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343250/ https://www.ncbi.nlm.nih.gov/pubmed/35752657 http://dx.doi.org/10.1038/s41375-022-01629-7 |
| _version_ | 1784760971032526848 |
|---|---|
| author | von Tresckow, Julia Cramer, Paula Robrecht, Sandra Langerbeins, Petra Fink, Anna-Maria Al-Sawaf, Othman Fürstenau, Moritz Illmer, Thomas Klaproth, Holger Tausch, Eugen Ritgen, Matthias Fischer, Kirsten Wendtner, Clemens-Martin Kreuzer, Karl-Anton Stilgenbauer, Stephan Böttcher, Sebastian Eichhorst, Barbara F. Hallek, Michael |
| author_facet | von Tresckow, Julia Cramer, Paula Robrecht, Sandra Langerbeins, Petra Fink, Anna-Maria Al-Sawaf, Othman Fürstenau, Moritz Illmer, Thomas Klaproth, Holger Tausch, Eugen Ritgen, Matthias Fischer, Kirsten Wendtner, Clemens-Martin Kreuzer, Karl-Anton Stilgenbauer, Stephan Böttcher, Sebastian Eichhorst, Barbara F. Hallek, Michael |
| author_sort | von Tresckow, Julia |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9343250 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93432502022-08-03 Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial von Tresckow, Julia Cramer, Paula Robrecht, Sandra Langerbeins, Petra Fink, Anna-Maria Al-Sawaf, Othman Fürstenau, Moritz Illmer, Thomas Klaproth, Holger Tausch, Eugen Ritgen, Matthias Fischer, Kirsten Wendtner, Clemens-Martin Kreuzer, Karl-Anton Stilgenbauer, Stephan Böttcher, Sebastian Eichhorst, Barbara F. Hallek, Michael Leukemia Letter Nature Publishing Group UK 2022-06-25 2022 /pmc/articles/PMC9343250/ /pubmed/35752657 http://dx.doi.org/10.1038/s41375-022-01629-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Letter von Tresckow, Julia Cramer, Paula Robrecht, Sandra Langerbeins, Petra Fink, Anna-Maria Al-Sawaf, Othman Fürstenau, Moritz Illmer, Thomas Klaproth, Holger Tausch, Eugen Ritgen, Matthias Fischer, Kirsten Wendtner, Clemens-Martin Kreuzer, Karl-Anton Stilgenbauer, Stephan Böttcher, Sebastian Eichhorst, Barbara F. Hallek, Michael Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial |
| title | Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial |
| title_full | Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial |
| title_fullStr | Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial |
| title_full_unstemmed | Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial |
| title_short | Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial |
| title_sort | sequential treatment with bendamustine, obinutuzumab (ga101) and ibrutinib in chronic lymphocytic leukemia (cll): final results of the cll2-big trial |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343250/ https://www.ncbi.nlm.nih.gov/pubmed/35752657 http://dx.doi.org/10.1038/s41375-022-01629-7 |
| work_keys_str_mv | AT vontresckowjulia sequentialtreatmentwithbendamustineobinutuzumabga101andibrutinibinchroniclymphocyticleukemiacllfinalresultsofthecll2bigtrial AT cramerpaula sequentialtreatmentwithbendamustineobinutuzumabga101andibrutinibinchroniclymphocyticleukemiacllfinalresultsofthecll2bigtrial AT robrechtsandra sequentialtreatmentwithbendamustineobinutuzumabga101andibrutinibinchroniclymphocyticleukemiacllfinalresultsofthecll2bigtrial AT langerbeinspetra sequentialtreatmentwithbendamustineobinutuzumabga101andibrutinibinchroniclymphocyticleukemiacllfinalresultsofthecll2bigtrial AT finkannamaria sequentialtreatmentwithbendamustineobinutuzumabga101andibrutinibinchroniclymphocyticleukemiacllfinalresultsofthecll2bigtrial AT alsawafothman sequentialtreatmentwithbendamustineobinutuzumabga101andibrutinibinchroniclymphocyticleukemiacllfinalresultsofthecll2bigtrial AT furstenaumoritz sequentialtreatmentwithbendamustineobinutuzumabga101andibrutinibinchroniclymphocyticleukemiacllfinalresultsofthecll2bigtrial AT illmerthomas sequentialtreatmentwithbendamustineobinutuzumabga101andibrutinibinchroniclymphocyticleukemiacllfinalresultsofthecll2bigtrial AT klaprothholger sequentialtreatmentwithbendamustineobinutuzumabga101andibrutinibinchroniclymphocyticleukemiacllfinalresultsofthecll2bigtrial AT tauscheugen sequentialtreatmentwithbendamustineobinutuzumabga101andibrutinibinchroniclymphocyticleukemiacllfinalresultsofthecll2bigtrial AT ritgenmatthias sequentialtreatmentwithbendamustineobinutuzumabga101andibrutinibinchroniclymphocyticleukemiacllfinalresultsofthecll2bigtrial AT fischerkirsten sequentialtreatmentwithbendamustineobinutuzumabga101andibrutinibinchroniclymphocyticleukemiacllfinalresultsofthecll2bigtrial AT wendtnerclemensmartin sequentialtreatmentwithbendamustineobinutuzumabga101andibrutinibinchroniclymphocyticleukemiacllfinalresultsofthecll2bigtrial AT kreuzerkarlanton sequentialtreatmentwithbendamustineobinutuzumabga101andibrutinibinchroniclymphocyticleukemiacllfinalresultsofthecll2bigtrial AT stilgenbauerstephan sequentialtreatmentwithbendamustineobinutuzumabga101andibrutinibinchroniclymphocyticleukemiacllfinalresultsofthecll2bigtrial AT bottchersebastian sequentialtreatmentwithbendamustineobinutuzumabga101andibrutinibinchroniclymphocyticleukemiacllfinalresultsofthecll2bigtrial AT eichhorstbarbaraf sequentialtreatmentwithbendamustineobinutuzumabga101andibrutinibinchroniclymphocyticleukemiacllfinalresultsofthecll2bigtrial AT hallekmichael sequentialtreatmentwithbendamustineobinutuzumabga101andibrutinibinchroniclymphocyticleukemiacllfinalresultsofthecll2bigtrial |